Extrapolated Biosimilar Indications Won't Get More US Post-Marketing Requirements
This article was originally published in PharmAsia News
Executive Summary
Biosimilars will have the same pharmacovigilance expectations as innovator biologics in the US despite the lack of clinical data for some extrapolated indications.
You may also be interested in...
Biosimilar Interchangeability Requirements Pushed At Inflectra Review
Celltrion is not seeking interchangeable status, but it had data on a single transition from EU-approved Remicade; however, FDA's advisors said data on multiple switches between products would more accurately reflect real-world clinical practice.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.